Luxembourg’s Eurofins expands through acquisition in Germany

Eurofins Scientific, a global leader in bio-analytical testing, and one of the world leaders in genomic services, announces the acquisition of MVZ für Laboratoriumsmedizin am Hygiene-Institut GmbH (“Hygel”), a group of clinical diagnostic laboratories headquartered in Gelsenkirchen, Germany. The transaction is expected to close at the beginning of July, subject to the fulfilment of customary closing conditions.
Founded in 1902, Hygel has developed into one of the largest clinical diagnostics providers in North Rhine-Westphalia, the most populous federal state in Germany, with access to over 900 physicians, 120 hospitals and around 20 local health authorities. As a reference clinical laboratory, Hygel serves more than 50% of the healthcare industry in the Northern Ruhr area and Iserlohn region, with multiple accreditations from both private and public health authorities and agencies. The company employs 370 staff across its 3 main sites as well as in laboratories that it operates for 4 local hospitals, and generated revenues in excess of EUR 35m in 2016.
The acquisition of Hygel provides Eurofins entry into the clinical diagnostic testing market in Germany, and reinforces the Group’s footprint to serve healthcare professionals in Europe. In return, Eurofins’ vast analytical portfolio and technical resources, as well as the Group’s world class laboratory and systems infrastructure, should support the further development of Hygel’s portfolio of diagnostic tests and services, as well as the expansion of its footprint and client reach in the rest of the country.
Dr Astrid Dirkes-Kersting, Managing Director, Hygel said: “We are excited to be joining the Eurofins family of laboratories and look forward to the next phase of our development within the Group. We are confident that with access to Eurofins’ network and technical competencies, we should be able to expand our analytical portfolio and services to benefit all our existing and future clients.”
Dr Gilles Martin, Eurofins CEO, said: “The acquisition of Hygel expands Eurofins’ clinical diagnostic footprint in Europe, and reinforces the platform on which to deploy the Group’s technical know-how and proprietary technologies, including our competencies in specialty diagnostic testing. We are committed to supporting Hygel in further developing its service offering and its geographic footprint to better serve the healthcare industry in Germany.”